Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19325274 | 0.83 | DAO (0.43) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL25799818 | 0.83 | DAO (0.43) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL24879524 | 0.83 | DAO (0.48) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL20204799 | 0.79 | DAO (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL25054107 | 0.79 | DAO (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL25330569 | 0.79 | DAO (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL18800357 | 0.79 | DAO (0.41) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL25023927 | 0.78 | MCL1 (0.48) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL23564693 | 0.78 | DAO (0.39) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL908781 | 0.77 | KDM4E (0.47) | DAOAURKAAURKBINCENPMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| EP-4289833-A1 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | PFIZER LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | DAO 2786/4885AURKA 3619/4885AURKB 2923/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | DAO 806/4885AURKA 3513/4885AURKB 2993/4885 |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | DAO 1032/4885AURKA 3186/4885AURKB 3917/4885 |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | DAO 2998/4885AURKA 3420/4885AURKB 3116/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | DAO 147/4885AURKA 2983/4885AURKB 1887/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | DAO 835/4885AURKA 2613/4885AURKB 1999/4885 |
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | DAO 2644/4885AURKA 3380/4885AURKB 2687/4885 |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | ADRB2, ADRB1, ADRA2C | DAO 1970/4885AURKA 3335/4885AURKB 2877/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | DAO 1500/4885AURKA 2822/4885AURKB 1364/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | DAO 3003/4885AURKA 3632/4885AURKB 1862/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | DAO 3398/4885AURKA 4722/4885AURKB 3852/4885 |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | MET, REL, NAT1 | DAO 129/4885AURKA 3283/4885AURKB 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.